NUTX vs. AUGX, AMWL, RPID, MODD, RVPH, ESLA, MRKR, QNCX, ICCC, and SNSE
Should you be buying Nutex Health stock or one of its competitors? The main competitors of Nutex Health include Augmedix (AUGX), American Well (AMWL), Rapid Micro Biosystems (RPID), Modular Medical (MODD), Reviva Pharmaceuticals (RVPH), Estrella Immunopharma (ESLA), Marker Therapeutics (MRKR), Quince Therapeutics (QNCX), ImmuCell (ICCC), and Sensei Biotherapeutics (SNSE). These companies are all part of the "medical" sector.
Nutex Health (NASDAQ:NUTX) and Augmedix (NASDAQ:AUGX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
5.3% of Nutex Health shares are held by institutional investors. Comparatively, 87.1% of Augmedix shares are held by institutional investors. 38.5% of Nutex Health shares are held by insiders. Comparatively, 11.0% of Augmedix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Nutex Health had 1 more articles in the media than Augmedix. MarketBeat recorded 4 mentions for Nutex Health and 3 mentions for Augmedix. Augmedix's average media sentiment score of 1.25 beat Nutex Health's score of 0.93 indicating that Augmedix is being referred to more favorably in the news media.
Nutex Health has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Augmedix has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
Nutex Health received 2 more outperform votes than Augmedix when rated by MarketBeat users. Likewise, 100.00% of users gave Nutex Health an outperform vote while only 50.00% of users gave Augmedix an outperform vote.
Augmedix has lower revenue, but higher earnings than Nutex Health. Augmedix is trading at a lower price-to-earnings ratio than Nutex Health, indicating that it is currently the more affordable of the two stocks.
Nutex Health currently has a consensus price target of $15.00, indicating a potential upside of 2,038.28%. Augmedix has a consensus price target of $3.88, indicating a potential upside of 252.27%. Given Nutex Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Nutex Health is more favorable than Augmedix.
Nutex Health has a net margin of -15.85% compared to Augmedix's net margin of -41.95%. Nutex Health's return on equity of -44.06% beat Augmedix's return on equity.
Summary
Nutex Health beats Augmedix on 12 of the 18 factors compared between the two stocks.
Get Nutex Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nutex Health Competitors List
Related Companies and Tools
